Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 13 | 2023 | 371 | 1.680 |
Why?
|
| Glioblastoma | 11 | 2023 | 219 | 1.420 |
Why?
|
| Meningioma | 4 | 2023 | 54 | 0.680 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2019 | 29 | 0.600 |
Why?
|
| DNA Mismatch Repair | 3 | 2021 | 42 | 0.540 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2021 | 14 | 0.490 |
Why?
|
| Seizures | 3 | 2021 | 279 | 0.450 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 63 | 0.440 |
Why?
|
| Meningeal Neoplasms | 2 | 2023 | 42 | 0.400 |
Why?
|
| DNA Repair Enzymes | 3 | 2021 | 53 | 0.390 |
Why?
|
| DNA Repair | 2 | 2022 | 127 | 0.360 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 561 | 0.330 |
Why?
|
| Pentoxifylline | 1 | 2006 | 12 | 0.280 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2018 | 116 | 0.260 |
Why?
|
| Mutation | 4 | 2020 | 1213 | 0.260 |
Why?
|
| Vasodilator Agents | 1 | 2006 | 138 | 0.260 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2006 | 99 | 0.250 |
Why?
|
| Germ-Line Mutation | 2 | 2022 | 43 | 0.250 |
Why?
|
| Electroencephalography | 3 | 2021 | 418 | 0.230 |
Why?
|
| DNA Replication | 2 | 2022 | 167 | 0.220 |
Why?
|
| Re-Irradiation | 1 | 2022 | 1 | 0.220 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 30 | 0.200 |
Why?
|
| Biomarkers, Tumor | 3 | 2022 | 508 | 0.190 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 39 | 0.190 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2020 | 1 | 0.190 |
Why?
|
| Dendritic Cells | 2 | 2023 | 201 | 0.180 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2020 | 35 | 0.180 |
Why?
|
| Oncolytic Viruses | 1 | 2020 | 17 | 0.180 |
Why?
|
| Humans | 25 | 2023 | 68618 | 0.180 |
Why?
|
| Neurofibromin 2 | 1 | 2020 | 10 | 0.180 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 14 | 0.180 |
Why?
|
| Neoplasms | 3 | 2022 | 1667 | 0.170 |
Why?
|
| Quinolones | 1 | 2020 | 60 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 756 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 101 | 0.170 |
Why?
|
| Glioma | 1 | 2020 | 140 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 235 | 0.170 |
Why?
|
| Benzimidazoles | 1 | 2020 | 128 | 0.170 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 36 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2020 | 193 | 0.160 |
Why?
|
| Status Epilepticus | 1 | 2019 | 74 | 0.160 |
Why?
|
| Allyl Compounds | 1 | 2018 | 29 | 0.160 |
Why?
|
| Sulfides | 1 | 2018 | 43 | 0.160 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 61 | 0.150 |
Why?
|
| Young Adult | 6 | 2022 | 5717 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2019 | 159 | 0.150 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 99 | 0.150 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 1851 | 0.140 |
Why?
|
| Adult | 11 | 2022 | 21403 | 0.140 |
Why?
|
| Recurrence | 2 | 2023 | 948 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 454 | 0.130 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.130 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 30 | 0.130 |
Why?
|
| Gadolinium | 1 | 2016 | 88 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 87 | 0.130 |
Why?
|
| Limonins | 1 | 2015 | 10 | 0.130 |
Why?
|
| Catechols | 1 | 2015 | 14 | 0.130 |
Why?
|
| Flavones | 1 | 2015 | 11 | 0.130 |
Why?
|
| Lanosterol | 1 | 2015 | 11 | 0.130 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 14 | 0.130 |
Why?
|
| Heptanoic Acids | 1 | 2015 | 28 | 0.120 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 41 | 0.120 |
Why?
|
| Necrosis | 1 | 2015 | 239 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2015 | 97 | 0.120 |
Why?
|
| Triterpenes | 1 | 2015 | 40 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2023 | 3705 | 0.120 |
Why?
|
| Female | 10 | 2022 | 38074 | 0.110 |
Why?
|
| Injections, Spinal | 1 | 2013 | 18 | 0.110 |
Why?
|
| Cerebrospinal Fluid | 1 | 2013 | 23 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 163 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 511 | 0.110 |
Why?
|
| Skin | 1 | 2016 | 451 | 0.110 |
Why?
|
| Male | 11 | 2022 | 37321 | 0.110 |
Why?
|
| Contrast Media | 1 | 2016 | 595 | 0.110 |
Why?
|
| Child | 5 | 2022 | 6405 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2023 | 7277 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2018 | 7029 | 0.090 |
Why?
|
| Apoptosis | 4 | 2020 | 1641 | 0.090 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 213 | 0.090 |
Why?
|
| Adolescent | 4 | 2022 | 8912 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2020 | 223 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2022 | 714 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2021 | 3187 | 0.080 |
Why?
|
| Benzamides | 2 | 2020 | 156 | 0.070 |
Why?
|
| Middle Aged | 5 | 2021 | 21147 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 304 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 186 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1070 | 0.070 |
Why?
|
| Aged | 4 | 2021 | 14862 | 0.060 |
Why?
|
| Prevalence | 2 | 2021 | 1619 | 0.060 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1174 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3259 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2022 | 34 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 125 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2006 | 1738 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 931 | 0.050 |
Why?
|
| Preservation, Biological | 1 | 2022 | 11 | 0.050 |
Why?
|
| Tissue Preservation | 1 | 2022 | 44 | 0.050 |
Why?
|
| Risk | 1 | 2023 | 563 | 0.050 |
Why?
|
| Vaccination | 1 | 2023 | 189 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 171 | 0.050 |
Why?
|
| DNA Modification Methylases | 1 | 2020 | 24 | 0.050 |
Why?
|
| Sulfones | 1 | 2020 | 45 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2020 | 22 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2020 | 36 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 57 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2020 | 111 | 0.040 |
Why?
|
| Triazines | 1 | 2020 | 48 | 0.040 |
Why?
|
| Imidazoles | 1 | 2020 | 175 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2020 | 233 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2021 | 285 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 468 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 194 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2019 | 20 | 0.040 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2019 | 26 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2019 | 32 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2020 | 2689 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 215 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 1056 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 331 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 332 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2018 | 238 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 82 | 0.040 |
Why?
|
| DNA Polymerase III | 1 | 2017 | 3 | 0.040 |
Why?
|
| DNA Polymerase II | 1 | 2017 | 5 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2017 | 7 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 800 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1342 | 0.040 |
Why?
|
| Cell Line | 1 | 2021 | 1752 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 331 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 2223 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 219 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 4848 | 0.040 |
Why?
|
| Astrocytes | 1 | 2018 | 270 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 947 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1054 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 194 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 57 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 786 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2015 | 85 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 64 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1465 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1553 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 700 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 57 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1745 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 84 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2015 | 152 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 852 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2015 | 222 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 2358 | 0.030 |
Why?
|
| Neurons | 1 | 2018 | 881 | 0.030 |
Why?
|
| Kidney | 1 | 2016 | 945 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 2083 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 20881 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7367 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 5300 | 0.020 |
Why?
|